Orexo AB (publ)
Orexo AB (publ)
Your view on ORXOY
Overview
What the company does, where it operates, and who runs it.
About Orexo AB (publ)
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Nikolaj Sorensen
- Headquarters
- P.O. Box 303, Uppsala, SE
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Nikolaj Sorensen
- Headquarters
- P.O. Box 303, Uppsala, SE
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom.
Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia.
The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain.
It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder.
Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Orexo AB (publ), and the rating behind it. ORXOY last traded at $2.96; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Orexo AB (publ). Starting points for Orexo AB (publ): EPS -$8.78, beta 0.86 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Orexo AB (publ). Orexo AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Orexo AB (publ). Trailing twelve-month EPS for Orexo AB (publ) stands at -$8.78. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Orexo AB (publ). Orexo AB (publ) has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Orexo AB (publ) valued side by side against its closest peers. Orexo AB (publ) is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Orexo AB (publ), and how their positions are changing. At a $102.7M market value, institutional positions materially move Orexo AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Orexo AB (publ) executives and directors. Shares of Orexo AB (publ) have traded between $1.48 and $4.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Orexo AB (publ). Orexo AB (publ) is a $102.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Orexo AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Orexo AB (publ). Coverage tracks Orexo AB (publ) within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.